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Abstract: Around 90–95% of hepatitis B virus (HBV) infected adults do not progress to the
chronic phase and, instead, recover naturally. The strengths of the cytolytic and non-cytolytic
immune responses are key players that decide the fate of acute HBV infection. In addition, it has
been hypothesized that proliferation of infected cells resulting in uninfected progeny and/or
cytokine-mediated degradation of covalently closed circular DNA (cccDNA) leading to the cure of
infected cells are two major mechanisms assisting the adaptive immune response in the clearance
of acute HBV infection in humans. We employed fitting of mathematical models to human acute
infection data together with physiological constraints to investigate the role of these hypothesized
mechanisms in the clearance of infection. Results suggest that cellular proliferation of infected cells
resulting in two uninfected cells is required to minimize the destruction of the liver during the
clearance of acute HBV infection. In contrast, we find that a cytokine-mediated cure of infected cells
alone is insufficient to clear acute HBV infection. In conclusion, our modeling indicates that HBV
clearance without lethal loss of liver mass is associated with the production of two uninfected cells
upon proliferation of an infected cell.
Keywords: hepatitis B virus; hepatocyte turnover; cytokine-mediated cure of infected cells;
cellular proliferation
1. Introduction
Hepatitis B virus (HBV) is a highly prevalent infection with approximately 350 million chronic
carriers world-wide, causing about 1 million deaths each year [1]. Despite the existence of a safe
and efficacious vaccine, the current high prevalence, high mortality and lack of effective antiviral
therapy make HBV a severe health problem. Much effort has been expended in the past three
decades to comprehensively understand HBV [2–17]. In this quest, in vitro experiments along with
in vivo experiments in ducks, woodchucks, mice and chimpanzees have significantly improved our
understanding of HBV infection and its interaction with the immune system. Though experiments in
animal models and in vitro have provided important insights, some characteristics of HBV infection
are different in humans. One of the major differences is the higher number of covalently closed circular
DNA (cccDNA) molecules per infected cell in animal models compared to humans [18–22].
In particular, our understanding of acute HBV infection in humans is still very limited due to the
lack of data, as it is extremely difficult to find and sample people at this stage of infection. Nonetheless,
some data is available [6] and mathematical models can be used along with this data to investigate
possible mechanisms underlying the clearance of acute HBV infection.
In the past, mathematical models have been used extensively to study the viral dynamics of infections
such as HBV, hepatitis C virus (HCV) and human immunodeficiency virus (HIV) [5,6,13,23–38]. Here,
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we propose new mathematical models and investigate different mechanisms related to the natural
clearance of acute HBV infection, using a longitudinal dataset of six acutely HBV infected individuals,
who naturally cleared the infection [6].
Although the majority of adults infected with HBV clear infection [39,40], how this occurs is not
fully understood. The clearance of acute HBV infection correlates with the strengths of the cytolytic
and non-cytolytic immune responses [41,42]. It is thought that cytotoxic T lymphocytes (CTL or T-cells)
clear infection by inducing the death of infected cells while non-cytolytic mechanisms involve antiviral
cytokines, such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), that inhibit intracellular
HBV replication and thus assist in the control of HBV infection [9,43–47]. There are two other
mechanisms whose importance in the clearance of acute HBV infection has been debated [9,44,48,49].
The first involves the substantial loss of cccDNA during proliferation of infected cells [50–53], while the
second assumes that cytokines can also induce the degradation of cccDNA (in addition to the inhibition
of the intracellular HBV replication), which then leads to the cure of infected cells (this mechanism is
referred to as cytokine-mediated cure of infected cells) [44]. The loss of cccDNA upon cell division
could occur if cccDNA failed to be reincorporated into the nucleus when the nuclear membrane reforms
during mitosis. Also, cccDNA can be lost by dilution during cell proliferation and if the cccDNA copy
number were small, due to random segregation of cccDNA between daughter cells some cells may
fail to inherit any cccDNA. It is important to understand the role of these additional mechanisms
in the resolution of acute HBV infection. This is because acute HBV infection can be cleared in 8 to
12 weeks in the presence of limited immune responses [54,55] despite nearly all hepatocytes being
infected with HBV at the peak of acute infection [4,22,55,56], with each infected cell containing at
least one cccDNA molecule with an estimated half-life of around 50 days [57]. In vivo and in vitro
experiments have hinted that these two additional mechanisms could be important in the clearance of
HBV acute infection [44,51,52,58,59]; however, these studies were not conclusive [60,61]. In addition,
a recently conducted computational study showed the importance of cccDNA loss during cellular
proliferation in the process of non-destructive clearance of HBV infection [24]. To investigate this with
human data, we developed models to test three hypotheses on the effect of infected cell proliferation:
it produces (i) two uninfected daughter cells, (ii) two infected daughter cells or (iii) one uninfected and
one infected daughter cell. We also tested if cytokine-mediated cure of infected cells is able to clear
acute HBV infection.
2. Materials and Methods
2.1. Patient Data
Whalley et al. [6] identified 7 patients infected in the acute phase of HBV infection. Data from
patient 7, treated with the reverse transcriptase inhibitor lamivudine, is not representative of the
natural course of the disease and was excluded from the present study. HBV DNA in serum was
measured longitudinally in the remaining six patients for up to 150 days [6]. Ultimately, all these
six patients cleared HBV infection. We assume that the effect of immune-mediated clearance starts
at the peak of viremia for each patient, as we did before [25]. The patient data is provided in the
supplementary information (Table S1).
2.2. Mathematical Models
The liver consists mostly of hepatocytes and a variety of nonparenchymal cells. Hepatocytes
are responsible for many of the crucial functions of the liver and are the primary target for HBV.
The liver, if damaged, can regenerate and thus hepatocytes, even though highly differentiated, retain
the capacity to proliferate. One criterion that we use to access the realism of a model is whether the
proliferative response to infection maintains the number of hepatocytes above a critical threshold
needed for adequate functioning. Thus, it is important to know the number of hepatocytes in a healthy
liver. The literature suggests that hepatocytes are ~60% of the 2 × 1011 cells in an adult liver [62–65].
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2.2.1. Models Characterizing Different Outcomes of the Cellular Proliferation of Infected Cells
We develop mathematical models to investigate three scenarios regarding infected hepatocyte
proliferation. When an infected cell divides it can generate (i) two uninfected daughter cells (Model 1),
(ii) two infected daughter cells (Model 2), and (iii) one uninfected and one infected daughter cell
(Model 3).
T, I and V represent concentration of target cells, infected cells and the concentration in serum of
HBV DNA, respectively. Infection occurs with infectivity rate constant k while infected cells die at per
capita rate δ. The per infected cell production rate of HBV is denoted by pV and cV is the clearance rate
of HBV. Here, θ is the fraction of liver cells that cannot be infected (i.e., nonparenchymal cells) in the
total liver cell population and H is the total liver cell population before infection, which includes both
hepatocytes and nonparenchymal cells. Both θ and H are assumed to be constants. Additionally, we
assume that uninfected and infected hepatocytes proliferate according to a logistic growth law with
rT and rI , respectively. By using a logistic growth law, the total number of liver cells can never grow
larger than H. We simplify our model by assuming r = rT = rI to reduce the number of unknown
parameters. With these assumptions, the three models are described by the following equations
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M3 can also represent a model where cellular proliferation results, on average, in the loss of
cccDNA 50% of the time and preservation of cccDNA 50% of the time.
2.2.2. Model Incorporating Cytokine-Mediated Cure of Infected Cells
We also investigate two additional models in which there is cytokine-mediated cure of
infected cells.
Model 4 (M4)-Proliferation of an Infected Cell Produces Two Infected Cells and There Is
Cytokine-Mediated Cure of Infected Cells
In this model, we assume that proliferation of an infected cell produces two infected cells and that
there is cytokine-mediated degradation of cccDNA, which results in the loss of infected cells at rate ρI,
without cell death. This model, M4, is derived by subtracting the term ρI in the second equation and
adding it in the first equation of M2.
Model 5 (M5)-Proliferation of an Infected Cell Produces Two Uninfected Cells and There Is
Cytokine-Mediated Cure of Infected Cells
Finally, in this model we assume that proliferation of an infected cell produces two uninfected
cells and there is cytokine-mediated cure of infected cells (the term ρI). Thus, we subtract and add the
term ρI in the second and first equation respectively of M1, and refer to it as M5.
2.3. Parameter Values and Simulation Procedure
We take H = 13.6 × 106 cells/mL as in prior studies [66]. In chimpanzees, mice and ducks,
95–99% of hepatocytes are infected at the peak of acute infection [19,26]. In addition, from a modeling
study the mean fraction of HBV infected hepatocytes in humans at the peak of infection has been
estimated to be at least 95% [66]. As the human viral load data from [6] that we analyze was first
collected near peak viremia, we let t = 0 refer to the time of peak viremia and the corresponding
viral load at peak as V(0). At this time, we assume I(0) = 0.95(1 − θ)H and T(0) = 0.05(1 − θ)H,
where I(0) and T(0) are the infected and uninfected hepatocyte populations respectively at time t = 0,
i.e., the peak of viral load in acute infection. In addition, (1 − θ) is the fraction of the total number of
cells in the liver (H) that are hepatocytes, and thus HBV targets. We first simulated models M1–M3
and estimated the default value of the virus infectivity parameter as the maximum value of k under
which all patients satisfy all the model selection criteria (discussed in the Section 2.4) under any one
of the three models. The default value of k was estimated to be 0.55 × 10−10 mL/copies·day (see
Tables S2–S5). In Section 3.5.1, we perform sensitivity analysis on the choice of virus infectivity, k, and
the size of the initial infected and uninfected hepatocyte populations, I(0) and T(0). Furthermore, we
assumed θ = 0.4 corresponding to 60% of liver cells being hepatocytes [62,63,67].
In order to estimate the four unknown parameters, namely, r, δ, pV and cV , we used the
Levenberg–Marquardt algorithm embedded in the optimization procedure “lsqnonlin” in MATLAB
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R2016b (The Mathworks, Inc., Natick, MA, USA) to fit the different models to the viral load data
obtained from the 6 patients. We also estimate the parameter ρ associated with models M4 and M5
and constrain ρ to be between 0.001 and 0.35/day [24]. To avoid local minima, we perform fitting
with 100 random initial parameter guesses for each patient, and then choose the parameters with the
lowest error, where error is given by RSS = ∑nVi=1(log 10(Vi)− log 10(Vi))
2, and i = 1, 2 . . . , nV refer
to the viral load data points, Vi, and the analogous value given by our model is Vi [68]. Note that in
comparing the initial guesses, we are comparing models with the same number of parameters on the
same data set.
In the estimation procedure, we constrained the parameter search over biologically reasonable
ranges. Thus, we assumed a minimum value of δ = 0.001/day [69,70] but left the maximum value
unconstrained. In addition, the value of r was constrained to be between 0.001 and 3.4/day [71,72].
Similarly, the value of cV was constrained to be between 0.67 and 4.2/day [13,66]. Cytokines are
recruited during the clearance of acute infection and they are present post-peak in acute HBV infection
contributing to the inhibition of HBV replication [54]. Therefore, we assume that the maximum value
of viral production, pV occurs at the peak of the infection. This maximum value is determined by
the fact that dV/dt = 0 at peak viremia and therefore the production rate of HBV at t = 0, i.e., at
peak viremia, is cVV(0)/I(0). We estimate pV from the data fitting and since that value is less than
the maximum value at t = 0, we take this to mean that non-cytolytic inhibition of viral production by
cytokines may be occurring. The average efficacy of the inhibition of HBV replication by cytokines can
be given by 1 − pV I(0)/cVV(0).
To compare models, we use the corrected Akaike information criterion (AICC) calculated as
AICC = (nln(RSS/n)) + (2mn/(n − m − 1)), where m is the number of unknown parameters and n is
the number of data points used in the fits [68,73,74]. We also calculate the total AICC with total residual
sum of squares over all patients as RSS, while n and m as the total number of data points and unknown
parameters over all patients, respectively. The smaller the AICC, the better the model is supported by
the data. However, when the AICC difference between two models is less than 2, both models have
equal support. When this difference is between 4 and 7, then the evidence for better support of one
model over another is weak. If it is more than 10, then the evidence is strong [75,76].
2.4. Criteria to Determine the Biological Plausibility of the Model
Apart from a good-fit to the viremia data, the desired outcomes include clearance of the infection
while maintaining liver integrity and complete elimination of the infected cell population to avoid
relapse. The first criterion of non-destructive clearance is the amount of hepatocyte turnover (HT),
defined as the number of hepatocytes (normalized to the total number of hepatocytes in an uninfected




(1−θ)H dt, which has been
estimated to be in the range of 0.35–3 [14,24,25,53,77] during immune-mediated clearance in 12 weeks.
Alongside, HT should be as low as possible because persistent apoptosis over a long period also serves
as a mechanism of liver injury and carcinogenesis [78]. Therefore, we use HT < 3 as a measure of
non-destructive clearance of acute HBV infection in humans, with a preference for HT to be as low
as possible to avoid the possibility of liver injury and/or scarring. The second criterion requires that
the infected cell population decrease to less than one cell to reflect true clearance of HBV infection.
We also calculate the number of hepatocytes (normalized to the total number of hepatocytes in an
uninfected adult liver) cured by cytokines in the process of cytokine-mediated cure of infected cells,





In studies of liver transplant from living donors, a hepatic resection leaving more than 20–30%
of the original liver volume is considered safe and allows liver regeneration in the donor [79–81].
Kishi et al. studying more than 300 patients with extended right lobe hepatectomies found that having
a liver remnant volume >20% is sufficient for safe hepatic resection [81]. As there can also be further
hepatocyte cell death after liver resection due to ischemia reperfusion injury [79], which does not occur
during HBV infection, we assumed that in acute HBV infection having 20% of the original hepatocyte
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number (i.e., 0.12H) is sufficient for maintaining the essential functions of the liver, but anything less
than 20% can be fatal. Thus, a second model criterion is having the hepatocyte number remain above
0.12H. We note that in terms of liver cell population size, this critical level corresponds to at least 52%
of the liver cells still remaining (the sum of (i) θH = 0.4H from the constant nonparenchymal cell
population, and (ii) 0.12H from the hepatocyte cell population). Based on this we will reject models in
which the predicted liver cell number falls below 52% (or the hepatocyte number falls below 20%) of
their original numbers.
3. Results
3.1. Fitting to Viral Load Data Alone Does Not Differentiate Models
First, we checked whether the fit of M1, M2 and M3 to the HBV viremia data is sufficient to
differentiate between the fates of cccDNA during cell division of infected cells by comparing the
AICC for models 1, 2 and 3 (Table S6). With lower AICC for each patient (and also lower total AICC),
our simulations showed better support for M1 over M2 and M3 for all 6 patients. However, we also
found that the differences in AICC among the models for the 6 patients is too small to reach definite
conclusions (shown for P1 in Figure 1A,C,E). Therefore, we cannot choose the best model just based on
fitting to patient HBV viremia data.
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The experimental data show that all six patients cleared acute HBV infection without critical 
liver destruction and therefore in the next section we track the infected cell population to check for 
the true clearance of acute HBV infection in these 6 patients. 
3.2. Biological Constraints Indicate that Proliferation of Infected Cells is More Likely to Produce Two 
Uninfected Cells 
We next considered the predictions of the three models concerning hepatocyte turnover and the 
size of the liver throughout acute infection. We impose the conditions that the hepatocyte turnover 
should be less than 3 and that the liver cell population during the clearance ( + + ) never 
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The experimental data show that all six patients cleared acute HBV infection without critical liver
destruction and therefore in the next section we track the infected cell population to check for the true
clearance of acute HBV infection in these 6 patients.
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3.2. Biological Constraints Indicate that Proliferation of Infected Cells is More Likely to Produce Two
Uninfected Cells
We next considered the predictions of the three models concerning hepatocyte turnover and the
size of the liver throughout acute infection. We impose the conditions that the hepatocyte turnover
should be less than 3 and that the liver cell population during the clearance (I + T + θH) never becomes
smaller than 52% of the total liver cell population before infection (H).
The best-fits of the models to the data revealed that M1, where an infected cell produces two
uninfected cells is the only model which not only produces a good fit to the HBV viremia (see total
AICC in Table S6) but also maintains a functioning liver for all patients during the process of infection
clearance (Table 1). In particular, patient 1 (P1) plays an important role in distinguishing the three
models because we observed more than 5 log (first-phase) decrease in HBV viremia in this patient.
In contrast to M1, models M2 and M3 showed significant liver destruction/dysfunction during the
clearance of acute HBV infection, in particular for P1 (see Figure 1B,D,F and Table 1). Model 2, where
proliferation of an infected cell generates two infected cells, results in a non-functioning liver (with the
total liver cell population during clearance (I + T + θH) decreasing below 52% of the total liver cell
number before infection (H)) for all patients (see bold and underlined numbers in Table 1). Over all
patients, M1 also resulted in the clearance of acute HBV infection with lowest mean HT (0.87) compared
to M2 (1.14) and M3 (1.05).
Table 1. Hepatocyte turnover (HT) and (%) Lowest liver cell number (LCN) under models M1, M2
and M3. Here, LCN represents the lowest liver cell number during the process of infection clearance
as a fraction of H. The critical LCN threshold to maintain liver integrity is 52%. Bold and underlined
numbers represents the case of liver-destruction and/or loss of liver integrity.
Model Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
M1
HT 1.26 0.72 0.83 0.84 0.78 0.82
LCN 52.6 91.8 69.3 72.4 79.3 75
M2
HT 1.5 1.27 1.02 1.0 1.05 1.01
LCN 43.8 51.1 44.1 42.9 45.5 43.5
M3
HT 1.34 0.98 0.99 1.0 0.98 0.99
LCN 49.6 83.5 98.3 64.8 66 68.5
3.3. Cytokine-Mediated Cure of Infected Cells is Insufficient to Achieve Non-Destructive Clearance of Acute
HBV Infection
Another process hypothesized to assist clearance of HBV infection is cytokines mediated
destabilization of cccDNA (and possibly cure of infected cells) [44,49,58]. Therefore, we investigated
this mechanism under model M4 (via the term ρI in the model). In this model, we also assumed
that infected cell proliferation results in two infected cells, because we want to test the ability of
cytokine-mediated cure to clear HBV infection by itself (see Section 3.4 for another possibility).
We find that the data does not support this model as well as M1–M3, since the total AICc for M4
(81.9) is more than 30 points higher than the AICc score for models M1–M3 (Table S6). Moreover, we
find that cytokines-mediated cure of HBV infected cells is insufficient to clear acute HBV infection in
all six patients without liver dysfunction (see P1 in Table 2). We also find that the number of infected
cells that become uninfected due to cytokine-mediated cccDNA degradation is very small (and close
to zero) for patient 1 (non-destructive turnover (NDT) in Table 2 and ρ in Table S8). This could be due
to the observed >5 log first-phase decrease in HBV viremia in patient 1.
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Table 2. Hepatocyte turnover (HT), (%) Lowest liver cell number (LCN), non-destructive turnover
(NDT) under models M4 and M5. Here, LCN represents the lowest liver cell number as a fraction of H
during the process of infection clearance and NDT denotes the number of cured hepatocytes measured
in original hepatocyte number equivalents. The critical threshold of the liver cell number to maintain
liver integrity is 52%. Bold and underlined figures represents the case of liver-destruction and/or
non-functionality of the liver.
Model Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
M4
HT 1.49 0.16 0.12 0.01 0.02 0.03
LCN 43.8 93.6 98.2 99.5 98.9 99.8
NDT 0.001 0.851 0.905 1.01 0.963 0.984
M5
HT 1.26 0.69 0.7 0.84 0.62 0.79
LCN 52.7 92.3 98.5 72.1 98.8 76.7
NDT 0.002 0.047 0.008 0.006 0.113 0.029
3.4. Cytokine-Mediated Cure of Infected Cells and cccDNA Loss during Cellular Proliferation
Above, we tested whether cccDNA loss during cellular proliferation is more important than
cytokine-mediated cure of infected cells in clearing acute HBV infection. We found that cccDNA
loss during cellular proliferation had a more critical effect; however, it is also possible that these
two mechanisms act in concert. We investigated this phenomenon with model M5. The results are
summarized in Table 2.
The results for M5 (which is the same as M1 but incorporating cytokine-mediated cure of infected
cells) are similar to those of model M1. For example, both models reproduced the viral dynamics
without destruction of the liver (Tables 1 and 2).
However, the total AICC for M1 (45.8) was much smaller than for M5 (77.7), which has one
additional parameter per patient, indicating lack of support for the more complex model. Therefore,
M1 that did not include cytokine-mediated cure of infected cells performed better than the model
incorporating cytokine-mediated cure of infected cells. In summary, a model including complete loss
of cccDNA during cellular proliferation reproduces HBV viremia reasonably well without resulting in
liver destruction.
3.5. Model Robustness
3.5.1. Sensitivity to Viral Infectivity
In order to determine the sensitivity of our results to the fixed value of the virus infectivity
parameter, k, we varied it in the range [0.1k , 2k], where k = 0.55 × 10−10 while keeping the value of
the other parameters constant. We then determined the impact of this change on outputs such as HT
and (%) lowest liver cell number (LCN) for patients P1 to P6 using models M1, M2, M3. The results are
summarized in Tables S2–S4.
We found that both HT and LCN were only slightly affected by the change in virus infectivity
for all patients except P1 under all models (Tables S2–S4). Models M2 and M3, where an infected cell
proliferates to generate at least one infected cell, result in a non-functioning liver for at least one of
the 6 patients for all values of virus infectivity (Tables S3 and S4). In fact, M2 had the most cases of
violations of these criteria of liver non-destruction (Table S3) followed by M3 (Table S4). In contrast,
M1 results in a functioning liver for all patients, although for P1 this is true only for values of virus
infectivity k ≤ 0.55 × 10−10 (Table S2). This is because we kept the values of parameters δ, pV , cV and
r fixed at their estimates obtained with k = 0.55 × 10−10.
However, if we refit the data for each value of the virus infectivity parameter in the range [0.1k , k],
M1 (but not M2 and M3) results in a functioning liver for all patients for all values of virus infectivity
(shown for P1 in Table S5). All values of k < 0.55× 10−10 can also be considered as cases of reduction in
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viral infectivity from its default value k = 0.55 × 10−10, possibly due to the emergence of HBV-specific
antibodies. Simulations showed that there is less liver injury (HT decreases while LCN increases) as we
decrease viral infectivity under all models; however the AICC increases at the same time. In conclusion,
only model M1 results in a functioning liver for all values of k while clearing acute HBV infection. If the
reduction in viral infectivity is less than 50%, then model M3 also fails to result in a functioning liver
while model M2 always fails even if the reduction in viral infectivity is as high as 90%. Even though
model M3 results in a functioning liver if the reduction in the viral infectivity is more than 50%, it still
performs worse than model M1 with no reduction in the viral infectivity (see AICC in Table S5).
3.5.2. Sensitivity to the Initial Infected Cell Population
We showed that M1 is the only model that results in the clearance of the acute HBV infection with
a functioning liver and lowest AICC. Therefore, we used M1 to analyze the model robustness relative
to the initial infected cell population at the viremia peak. We varied the peak infected cell population
between 85% and 99% of the initial hepatocyte population [66]. We also tested the robustness of
the model against an extreme case where the peak infected cell population is 50% of the initial
hepatocyte population.
We found that a change in the initial infected cell population has very little impact on HT and
LCN for all six patients (Table S9). Similar to the case above, we performed best-fit estimates for the
values of the parameters δ, pV , cV and r for all different initial infected cell population choices, and we
found that in all cases for all patients M1 resulted in a functioning liver.
3.6. Optimal Parameter Values for the 6 Acutely HBV Infected Patients
Using the best fits results for each patient under M1 and I(0) = 0.95× 0.6H, we report parameters
for individual patients in Table 3 (the associated HBV viremia fit and cell populations are given in
Figures 2 and 3, respectively). The median (range) for parameter δ is 0.065/day (0.03–0.58), while pV is
4.55 virions/cell day (0.06–788), cV is 0.75/day (0.67–0.92), r is 0.10/day (0.05–0.24) and HT is 0.825
(0.72–1.26).
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Table 3. Parameters for best fits for six patients using M1. The parameters δ, pV , cV , r, HT
and AICC represent the infected cell loss rate, the per infected cell production rate of HBV, the
clearance rate of HBV, the proliferation rate, hepatocyte turnover and corrected Akaike information
criterion, respectively.
Patient ffi/Day pV Vir/Cell·Day cV/Day r/Day HT AICC
Patient 1 0.58 788 0.92 0.20 1.26 14.08
Patient 2 0.03 5.7 0.83 0.24 0.72 −29.31
Patient 3 0.06 0.06 0.67 0.05 0.83 −15.66
Patient 4 0.09 5.30 0.67 0.10 0.84 9.94
Patient 5 0.05 1.80 0.67 0.10 0.78 23.96
Patient 6 0.07 3.8 0.87 0.10 0.82 19.77
Median 0.065 4.55 0.75 0.10 0.825Viruses 2017, 9, 350 10 of 17 
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greater than 15 times the upper limit of the normal range indicate severe acute liver cell injury [83],
consistent with the model prediction of substantial loss of hepatocytes near the ALT peaks (Figure 3).
Lastly, Guidotti et al. [9] observed that in acute HBV infection of chimpanzees a larger fraction of
hepatocytes were ongoing apoptosis than were in mitosis a few weeks after the viral load peak, also
consistent with hepatocyte loss.
4. Discussion
The immune system plays a very important role in the process of HBV infection clearance [41,42].
The antiviral immune response involves T cells, which kill infected cells and secrete cytokines
responsible for the inhibition of HBV replication, as well as B cells that secrete antibodies that neutralize
the virus [54]. An inefficient and weak immune response is associated with failure to clear acute HBV
infection and results in chronicity of HBV infection [84–86]. However, the clearance of acute HBV
infection in humans is intriguing as: (i) HBV infects nearly all hepatocytes at the peak of acute
infection [4,22,55,56], (ii) infected hepatocytes contain at least one cccDNA molecule, but possibly more
due to the transport of relaxed circular DNA (rcDNA) to the nucleus [25,87,88], (iii) template (cccDNA)
has a long half-life of around 7–8 weeks [57], and (iv) there is limited HBV-specific CTL precursor
frequency which can clear HBV infection [4]. And, yet clearance occurs in 8 to 12 weeks post-peak of
infection [54,55]. Summers et al. have estimated that in woodchucks clearance of WHV (the woodchuck
hepatitis virus model of HBV) infection could be achieved with liver turnover (including HT and
compensatory proliferation) as low as 0.7 [77]. However, these estimates are the lower bound and
the actual estimates could be more than 3 times these lower bounds due to the inefficiency of DNA
extraction in the experiments [53]. A modeling study also estimated the minimum liver turnover at
2.6 in resolving infection when there is only cytolytic death of infected cells and cccDNA survives
the process of cellular proliferation [14]. Furthermore, an agent-based modeling study found that
despite high HT, the cytolytic response alone is incapable of resolving acute HBV infection [24].
It should be noted that high HT implies high levels of death of HBV-infected hepatocytes, which
has important biological side-effects such as potential clonal expansion of mutant and epigenetically
altered hepatocytes [89].
Another key aspect of the immune response against HBV involves non-cytolytic effects (through
cytokines) that inhibit intracellular replication. Non-cytolytic mechanisms when added to the cytolytic
response significantly reduce HT and the burden on cytolytic cells by lowering the number of
infected cells required to be killed by each T cell each day [24,25,53]. However, we found that
even cytolytic and non-cytolytic mechanisms acting together fail to resolve infection in a time-frame of
8 to 12 weeks in recently conducted agent based 2-D and 3-D modeling studies of HBV infection [24,25].
Additional mechanisms, such as the loss of cccDNA during cellular proliferation of infected cells and
cytokine-mediated cure of infected cells, may significantly contribute towards the immune-mediated
clearance of acute HBV infection [9,44,48,49].
Here we investigated systematically both the effect of proliferation of infected cells and
cytokine-mediated cure of infected cells. A number of in vitro and in vivo experiments have hinted
that cccDNA and other intracellular HBV intermediates are lost during cellular proliferation [50–52].
One mechanism proposed to explain this phenomenon was that there is not enough time for
rcDNA to convert to cccDNA during rapid cell proliferation [51,90]. Another possible explanation
is that cccDNA is released from the nucleus when the nuclear membrane is disrupted during
mitosis and fails to be reincorporated in the nucleus when the nuclear membrane reforms [53,61].
An in vivo study by Ozer et al. [91] also showed an inverse correlation between the expression of
proliferating cell nuclear antigen (PCNA) and the presence of episomal HBV DNA in individual
hepatocytes. Recently, Dandri and Petersen also suggested that hepatocyte proliferation may accelerate
cccDNA decline [92]. Moreover, an in vivo study in humanized mice, which employed an advanced
(and precise) technique for measuring cccDNA, concluded that cccDNA is lost during cellular
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proliferation [50]. Some modeling studies also analyzed the importance of proliferation-induced
loss of cccDNA during clearance of acute HBV infection in chimpanzees [26] and in ducks [24,25].
Our data fitting suggested that cellular proliferation of infected cells is more likely to produce
two uninfected cells than one or two infected progeny. When we assumed that cccDNA is preserved
or only partially lost during cellular proliferation, clearance became more dependent on cell death
and the liver size often reduced to levels compromising its integrity. This was more prominently
evident in patient 1 where HBV viremia declined rapidly and became undetectable within 60 days
of the viremia peak. The mean proliferation rate among all patients was found to be 0.13/day, lower
than previous estimates [5] but much higher than the proliferation rate of quiescent hepatocytes [70].
The requirement for rapid proliferation during clearance is obvious, as it is desirable to make up for
the loss of liver mass, which results from death of infected cells. This rapid proliferation is enabled
by cytokines such as IFN-γ secreted by CD4+ T cells (in particular T-helper 1 cells), which induces
TNF-α and interleukin-6 (IL-6) that promote hepatocyte growth factor [84]. These cytokines have been
observed in adult individuals after acute HBV infection but not in chronic HBV patients [84].
Our simulations showed a significant decrease of up to nearly 80% in the hepatocyte population for
one patient under M1 during infection clearance. Even with such a significant decrease in hepatocytes,
the total liver cell number always remains greater than 52% of the number of cells in a normal liver.
Significant loss of hepatocytes is expected during acute HBV infection as ALT levels reach very high
levels (>15 times the normal upper limit), indicating severe acute liver cell injury [83]. Additionally,
Guidotti et al. [9] observed that in acute HBV infection of chimpanzees a larger fraction of hepatocytes
were ongoing apoptosis than were in mitosis a few weeks after the viral load peak, also consistent
with hepatocyte loss. The large decrease in the hepatocyte number in the simulations could also be
expected since the clearance of acute woodchuck hepatitis virus infection could involve hepatocyte loss
of up to 3 liver equivalents in a short period of time [14,24,25,53,77]. However, we do not know of any
experimental studies that explicitly confirm this large loss, in animal models or humans. Future studies
are needed to provide more quantitative information about the degree of liver loss during acute
HBV infection.
Our estimate of the mean half-life of infected cells of 2.1 days during the clearance of acute HBV
infection was similar to the estimate made by Whalley et al. of 3.7 ± 1.5 days [6]. Both estimates are
much shorter than previous estimates ranging between 10–100 days during chronic HBV infection
under antiviral therapy [93,94]. The longer estimated half-lives of infected hepatocytes during chronic
infection could reflect the exhaustion of CD8 effector cells, which makes them less effective killer
cells [95,96].
When we analyzed the effect of cytokine-mediated cure of infected cells, we found that it is
insufficient to simultaneously fit the measured viral load data and maintain necessary liver mass for
all patients, consistent with [24]. We also simulated the case where cccDNA is lost during cellular
proliferation together with cytokine-mediated cure of infected cells. However, this case showed no
improvement over the model without cytokine-mediated cure of infected cells. In this model, we did
not test the possibility that cytokines not only lead to cure of HBV infected cells, but also delay the
reinfection of newly cured cells.
The details of the control of liver cell proliferation during infection and clearance are not fully
known and it is unclear if they are similar to that seen after liver resection, which is better studied. After
liver resection, an increase in liver cell size is the first response to compensate for the liver loss, followed
by hepatocyte proliferation resulting in an increase of liver cell number [97,98]. We investigated a model
including the effect of an increase in hepatocyte cell size (Supplementary Material Section S1.1). In this
model, we first allow an increase in the cell size as a compensatory process for the lost liver mass
during the infection clearance and found that the major difference was the reduction in LCN in all
patients (Table S10).
Other mechanisms could also be studied. We have previously analyzed the possible impact of
HBV-specific antibodies in the control of HBV infection, as well as the effect of other putative immune
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responses [5,32]. In addition, one could explore the possibility of different proliferative capacities of
infected and uninfected hepatocytes. However, the probability of a huge difference in the proliferation
rate of infected and uninfected cells is small, as one study found that the recovered liver primarily
consists of cells derived from the infected cell population [14]. Models have been developed to test the
possibility that cytokines not only lead to cure of HBV infected cells but also delay reinfection of newly
cured cells [32,66]. Lastly, combinations of these mechanisms, the most likely scenario in vivo, could
be investigated. However, these more complex models will increase the number of parameters and
make it more difficult to fit the data adequately and interpret the results. For this reason, additional
experimental data related to the clearance of acute HBV infection in humans will further improve
such analysis.
In conclusion, clearance of acute HBV infection is likely dependent on cellular proliferation of an
infected cell resulting in two uninfected cells.
Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/9/11/350/s1.
Acknowledgments: This work was funded by National Institutes of Health grants R01-AI116868 (RMR),
R01-AI028433 (ASP) and R01-OD011095 (ASP). Portions of this work were performed under the auspices of the
U.S. Department of Energy under contract DE-AC52-06NA25396. The funding sponsors had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the
decision to publish the results. We also thank Geoffrey Dusheiko from UCL Institute of Liver and Digestive
Health, Kings College Hospital, UK for providing the data.
Author Contributions: Ashish Goyal, Alan S. Perelson and Ruy M. Ribeiro conceived and designed the
experiments; Ashish Goyal performed the experiments; Ashish Goyal, Alan S. Perelson and Ruy M. Ribeiro wrote
the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Locarnini, S.; Hatzakis, A.; Chen, D.S.; Lok, A. Strategies to control hepatitis B: Public policy, epidemiology,
vaccine and drugs. J. Hepatol. 2015, 62, S76–S86. [CrossRef] [PubMed]
2. Dandri, M.; Lutgehetmann, M.; Petersen, J. Experimental models and therapeutic approaches for HBV.
Semin. Immunopathol. 2013, 35, 7–21. [CrossRef] [PubMed]
3. Dandri, M.; Petersen, J. Latest developments in the treatment of hepatitis B. Minerva Gastroenterol. Dietol.
2016, 62, 88–102. [PubMed]
4. Chisari, F.V. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: Lessons from hepatitis B.
Am. J. Pathol. 2000, 156, 1117–1132. [CrossRef]
5. Ciupe, S.M.; Ribeiro, R.M.; Perelson, A.S. Antibody responses during hepatitis B viral infection. PLoS Comput. Biol.
2014, 10, e1003730. [CrossRef] [PubMed]
6. Whalley, S.A.; Murray, J.M.; Brown, D.; Webster, G.J.; Emery, V.C.; Dusheiko, G.M.; Perelson, A.S. Kinetics of
acute hepatitis B virus infection in humans. J. Exp. Med. 2001, 193, 847–854. [CrossRef] [PubMed]
7. Kock, J.; Schlicht, H.J. Analysis of the earliest steps of hepadnavirus replication: Genome repair after
infectious entry into hepatocytes does not depend on viral polymerase activity. J. Virol. 1993, 67, 4867–4874.
[PubMed]
8. Fourel, I.; Cullen, J.M.; Saputelli, J.; Aldrich, C.E.; Schaffer, P.; Averett, D.R.; Pugh, J.; Mason, W.S. Evidence
that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of
chronically infected ducks. J. Virol. 1994, 68, 8321–8330. [PubMed]
9. Guidotti, L.G.; Rochford, R.; Chung, J.; Shapiro, M.; Purcell, R.; Chisari, F.V. Viral clearance without
destruction of infected cells during acute HBV infection. Science 1999, 284, 825–829. [CrossRef] [PubMed]
10. Dandri, M.; Burda, M.R.; Will, H.; Petersen, J. Increased hepatocyte turnover and inhibition of woodchuck
hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.
Hepatology 2000, 32, 139–146. [CrossRef] [PubMed]
11. Walters, K.A.; Joyce, M.A.; Addison, W.R.; Fischer, K.P.; Tyrrell, D.L. Superinfection exclusion in duck
hepatitis B virus infection is mediated by the large surface antigen. J. Virol. 2004, 78, 7925–7937. [CrossRef]
[PubMed]
Viruses 2017, 9, 350 14 of 17
12. Chou, Y.C.; Jeng, K.S.; Chen, M.L.; Liu, H.H.; Liu, T.L.; Chen, Y.L.; Liu, Y.C.; Hu, C.P.; Chang, C. Evaluation
of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR
combined with the restriction enzyme digestion method. J. Virol. 2005, 79, 1813–1823. [CrossRef] [PubMed]
13. Murray, J.M.; Purcell, R.H.; Wieland, S.F. The half-life of hepatitis B virions. Hepatology 2006, 44, 1117–1121.
[CrossRef] [PubMed]
14. Mason, W.S.; Litwin, S.; Xu, C.; Jilbert, A.R. Hepatocyte turnover in transient and chronic hepadnavirus
infections. J. Viral Hepat. 2007, 14, 22–28. [CrossRef] [PubMed]
15. D’Ugo, E.; Canitano, A.; Catone, S.; Argentini, C.; Giuseppetti, R.; Orobello, S.; Palmieri, G.; Rapicetta, M.
Kinetics of WHV-HDV replication in acute fatal course of woodchuck hepatitis. Arch. Virol. 2008, 153,
2069–2076. [CrossRef] [PubMed]
16. Hantz, O.; Parent, R.; Durantel, D.; Gripon, P.; Guguen-Guillouzo, C.; Zoulim, F. Persistence of the hepatitis
B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J. Gen. Virol. 2009, 90,
127–135. [CrossRef] [PubMed]
17. Delius, H.; Gough, N.M.; Cameron, C.H.; Murray, K. Structure of the hepatitis B virus genome. J. Virol. 1983,
47, 337–343. [PubMed]
18. Zhang, Y.Y.; Zhang, B.H.; Theele, D.; Litwin, S.; Toll, E.; Summers, J. Single-cell analysis of covalently
closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc. Natl. Acad. Sci. USA 2003, 100,
12372–12377. [CrossRef] [PubMed]
19. Lutgehetmann, M.; Mancke, L.V.; Volz, T.; Helbig, M.; Allweiss, L.; Bornscheuer, T.; Pollok, J.M.; Lohse, A.W.;
Petersen, J.; Urban, S.; et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus
interactions and preclinical drug evaluation. Hepatology 2012, 55, 685–694. [CrossRef] [PubMed]
20. Nassal, M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut
2015, 64, 1972–1984. [CrossRef] [PubMed]
21. Thomas, H.C.; Lok, A.S.F.; Locarnini, S.A.; Zuckerman, A.J. Viral Hepatitis, 4th ed.; Wiley-Blackwell: Hoboken,
NJ, USA, 2013; p. 624.
22. Wieland, S.F.; Spangenberg, H.C.; Thimme, R.; Purcell, R.H.; Chisari, F.V. Expansion and contraction of the
hepatitis B virus transcriptional template in infected chimpanzees. Proc. Natl. Acad. Sci. USA 2004, 101,
2129–2134. [CrossRef] [PubMed]
23. Murray, J.M.; Stancevic, O.; Lutgehetmann, M.; Wursthorn, K.; Petersen, J.; Dandri, M. Variability in
long-term hepatitis B virus dynamics under antiviral therapy. J. Theor. Biol. 2016, 391, 74–80. [CrossRef]
[PubMed]
24. Murray, J.M.; Goyal, A. In silico single cell dynamics of hepatitis B virus infection and clearance. J. Theor. Biol.
2015, 366, 91–102. [CrossRef] [PubMed]
25. Goyal, A.; Murray, J.M. Modelling the impact of cell-to-cell transmission in hepatitis B virus. PLoS ONE 2016,
11, e0161978. [CrossRef] [PubMed]
26. Murray, J.M.; Wieland, S.F.; Purcell, R.H.; Chisari, F.V. Dynamics of hepatitis B virus clearance in chimpanzees.
Proc. Natl. Acad. Sci. USA 2005, 102, 17780–17785. [CrossRef] [PubMed]
27. Perelson, A.S. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2002, 2, 28–36. [CrossRef]
[PubMed]
28. Perelson, A.S.; Ribeiro, R.M. Hepatitis B virus kinetics and mathematical modeling. Semin. Liver Dis. 2004,
24, 11–16. [CrossRef] [PubMed]
29. Dahari, H.; Shudo, E.; Ribeiro, R.M.; Perelson, A.S. Modeling complex decay profiles of hepatitis B virus
during antiviral therapy. Hepatology 2009, 49, 32–38. [CrossRef] [PubMed]
30. Rong, L.; Perelson, A.S. Modeling latently infected cell activation: Viral and latent reservoir persistence,
and viral blips in HIV-infected patients on potent therapy. PLoS Comput. Biol. 2009, 5, e1000533. [CrossRef]
[PubMed]
31. Lewin, S.R.; Ribeiro, R.M.; Walters, T.; Lau, G.K.; Bowden, S.; Locarnini, S.; Perelson, A.S. Analysis of
hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology 2001, 34,
1012–1020. [CrossRef] [PubMed]
32. Ciupe, S.M.; Ribeiro, R.M.; Nelson, P.W.; Dusheiko, G.; Perelson, A.S. The role of cells refractory to productive
infection in acute hepatitis B viral dynamics. Proc. Natl. Acad. Sci. USA 2007, 104, 5050–5055. [CrossRef]
[PubMed]
Viruses 2017, 9, 350 15 of 17
33. Dahari, H.; Cotler, S.J.; Layden, T.J.; Perelson, A.S. Hepatitis B virus clearance rate estimates. Hepatology 2009,
49, 1779–1780. [CrossRef] [PubMed]
34. Ribeiro, R.M.; Germanidis, G.; Powers, K.A.; Pellegrin, B.; Nikolaidis, P.; Perelson, A.S.; Pawlotsky, J.M.
Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive
and negative infections. J. Infect. Dis. 2010, 202, 1309–1318. [CrossRef] [PubMed]
35. Zhang, L.; Dailey, P.J.; He, T.; Gettie, A.; Bonhoeffer, S.; Perelson, A.S.; Ho, D.D. Rapid clearance of simian
immunodeficiency virus particles from plasma of rhesus macaques. J. Virol. 1999, 73, 855–860. [PubMed]
36. Rong, L.; Perelson, A.S. Treatment of hepatitis C virus infection with interferon and small molecule direct
antivirals: Viral kinetics and modeling. Crit. Rev. Immunol. 2010, 30, 131–148. [CrossRef] [PubMed]
37. Castro, M.; Lythe, G.; Molina-Paris, C.; Ribeiro, R.M. Mathematics in modern immunology. Interface Focus
2016, 6, 20150093. [CrossRef] [PubMed]
38. Graw, F.; Perelson, A.S. Modeling viral spread. Annu. Rev. Virol. 2016, 3, 555–572. [CrossRef] [PubMed]
39. McMahon, B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49, S45–S55.
[CrossRef] [PubMed]
40. Ganem, D.; Prince, A.M. Hepatitis B virus infection–natural history and clinical consequences. N. Engl. J. Med.
2004, 350, 1118–1129. [CrossRef] [PubMed]
41. Dandri, M.; Locarnini, S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012, 61, i6–i17.
[CrossRef] [PubMed]
42. Bertoletti, A.; Ferrari, C. Innate and adaptive immune responses in chronic hepatitis B virus infections:
towards restoration of immune control of viral infection. Gut 2012, 61, 1754–1764. [CrossRef] [PubMed]
43. Pei, R.J.; Chen, X.W.; Lu, M.J. Control of hepatitis B virus replication by interferons and Toll-like receptor
signaling pathways. World J. Gastroenterol. 2014, 20, 11618–11629. [CrossRef] [PubMed]
44. Xia, Y.; Protzer, U. Control of hepatitis B virus by cytokines. Viruses 2017, 9, 18. [CrossRef] [PubMed]
45. Phillips, S.; Chokshi, S.; Riva, A.; Evans, A.; Williams, R.; Naoumov, N.V. CD8(+) T cell control of hepatitis B
virus replication: Direct comparison between cytolytic and noncytolytic functions. J. Immunol. 2010, 184,
287–295. [CrossRef] [PubMed]
46. Guidotti, L.G.; Ishikawa, T.; Hobbs, M.V.; Matzke, B.; Schreiber, R.; Chisari, F.V. Intracellular inactivation of
the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4, 25–36. [CrossRef]
47. Tsui, L.V.; Guidotti, L.G.; Ishikawa, T.; Chisari, F.V. Posttranscriptional clearance of hepatitis B virus RNA by
cytotoxic T lymphocyte-activated hepatocytes. Proc. Natl. Acad. Sci. USA 1995, 92, 12398–12402. [CrossRef]
[PubMed]
48. Seeger, C.; Mason, W.S. HBV replication, pathobiology and therapy: Unanswered questions. J. Hepatol. 2016,
64, S1–S3. [CrossRef] [PubMed]
49. Xia, Y.; Stadler, D.; Lucifora, J.; Reisinger, F.; Webb, D.; Hosel, M.; Michler, T.; Wisskirchen, K.; Cheng, X.;
Zhang, K.; et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence
form, cccDNA, without cytolysis. Gastroenterology 2016, 150, 194–205. [CrossRef] [PubMed]
50. Allweiss, L.; Volz, T.; Giersch, K.; Kah, J.; Raffa, G.; Petersen, J.; Lohse, A.W.; Beninati, C.; Pollicino, T.;
Urban, S.; et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection
efficiently deplete nuclear cccDNA in vivo. Gut 2017. [CrossRef] [PubMed]
51. Chong, C.L.; Chen, M.L.; Wu, Y.C.; Tsai, K.N.; Huang, C.C.; Hu, C.P.; Jeng, K.S.; Chou, Y.C.; Chang, C.
Dynamics of HBV cccDNA expression and transcription in different cell growth phase. J. Biomed. Sci. 2011,
18, 96. [CrossRef] [PubMed]
52. Lutgehetmann, M.; Volz, T.; Kopke, A.; Broja, T.; Tigges, E.; Lohse, A.W.; Fuchs, E.; Murray, J.M.; Petersen, J.;
Dandri, M. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed
circular DNA in mice. Hepatology 2010, 52, 16–24. [CrossRef] [PubMed]
53. Mason, W.S.; Xu, C.; Low, H.C.; Saputelli, J.; Aldrich, C.E.; Scougall, C.; Grosse, A.; Colonno, R.; Litwin, S.;
Jilbert, A.R. The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus
infections was lower when virus replication was inhibited with entecavir. J. Virol. 2009, 83, 1778–1789.
[CrossRef] [PubMed]
54. Bertoletti, A.; Gehring, A.J. The immune response during hepatitis B virus infection. J. Gen. Virol. 2006, 87,
1439–1449. [CrossRef] [PubMed]
55. Kennedy, P.T.F.; Litwin, S.; Dolman, G.E.; Bertoletti, A.; Mason, W.S. Immune tolerant chronic hepatitis B:
The unrecognized risks. Viruses 2017, 9, 96. [CrossRef] [PubMed]
Viruses 2017, 9, 350 16 of 17
56. Kajino, K.; Jilbert, A.R.; Saputelli, J.; Aldrich, C.E.; Cullen, J.; Mason, W.S. Woodchuck hepatitis-virus
infections - very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J. Virol.
1994, 68, 5792–5803. [PubMed]
57. Zhu, Y.; Yamamoto, T.; Cullen, J.; Saputelli, J.; Aldrich, C.E.; Miller, D.S.; Litwin, S.; Furman, P.A.; Jilbert, A.R.;
Mason, W.S. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol.
2001, 75, 311–322. [CrossRef] [PubMed]
58. Lucifora, J.; Xia, Y.; Reisinger, F.; Zhang, K.; Stadler, D.; Cheng, X.; Sprinzl, M.F.; Koppensteiner, H.;
Makowska, Z.; Volz, T.; et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
Science 2014, 343, 1221–1228. [CrossRef] [PubMed]
59. Lucifora, J.; Protzer, U. Attacking hepatitis B virus cccDNA—The holy grail to hepatitis B cure. J. Hepatol.
2016, 64, S41–S48. [CrossRef] [PubMed]
60. Chisari, F.V.; Mason, W.S.; Seeger, C. Virology. Comment on “Specific and nonhepatotoxic degradation of
nuclear hepatitis B virus cccDNA”. Science 2014, 344, 1237. [CrossRef] [PubMed]
61. Reaiche-Miller, G.Y.; Thorpe, M.; Low, H.C.; Qiao, Q.; Scougall, C.A.; Mason, W.S.; Litwin, S.; Jilbert, A.R.
Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing
liver. Virology 2013, 446, 357–364. [CrossRef] [PubMed]
62. Kuntz, E.; Kuntz, H.-D. Morphology of the Liver. In Hepatology Textbook and Atlas: History·Morphology
Biochemistry·Diagnostics Clinic·Therapy; Springer: Berlin/Heidelberg, Germany, 2008; p. 25.
63. Sherlock, S.; Dooley, J. Diseases of the Liver and Biliary System, 11th ed.; Blackwell Science: Oxford, UK, 2002.
64. Michalopoulos, G.K. Liver regeneration. J. Cell. Physiol. 2007, 213, 286–300. [CrossRef] [PubMed]
65. Kmiec, Z. Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Biol. 2001, 161, 1–151. [PubMed]
66. Ciupe, S.M.; Ribeiro, R.M.; Nelson, P.W.; Perelson, A.S. Modeling the mechanisms of acute hepatitis B virus
infection. J. Theor. Biol. 2007, 247, 23–35. [CrossRef] [PubMed]
67. Dandri, M.; Murray, J.M.; Lutgehetmann, M.; Volz, T.; Lohse, A.W.; Petersen, J. Virion half-life in chronic
hepatitis B infection is strongly correlated with levels of viremia. Hepatology 2008, 48, 1079–1086. [CrossRef]
[PubMed]
68. Pawelek, K.A.; Huynh, G.T.; Quinlivan, M.; Cullinane, A.; Rong, L.; Perelson, A.S. Modeling within-host
dynamics of influenza virus infection including immune responses. PLoS Comput. Biol. 2012, 8, e1002588.
[CrossRef] [PubMed]
69. Guedj, J.; Rotman, Y.; Cotler, S.J.; Koh, C.; Schmid, P.; Albrecht, J.; Haynes-Williams, V.; Liang, T.J.;
Hoofnagle, J.H.; Heller, T.; et al. Understanding early serum hepatitis D virus and hepatitis B surface
antigen kinetics during pegylated interferon-α therapy via mathematical modeling. Hepatology 2014, 60,
1902–1910. [CrossRef] [PubMed]
70. Furchtgott, L.A.; Chow, C.C.; Periwal, V. A model of liver regeneration. Biophys. J. 2009, 96, 3926–3935.
[CrossRef] [PubMed]
71. Reluga, T.C.; Dahari, H.; Perelson, A.S. Analysis of hepatitis C virus infection models with hepatocyte
homeostasis. SIAM J. Appl. Math. 2009, 69, 999–1023. [CrossRef] [PubMed]
72. Dahari, H.; Layden-Almer, J.E.; Kallwitz, E.; Ribeiro, R.M.; Cotler, S.J.; Layden, T.J.; Perelson, A.S.
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced
liver disease. Gastroenterology 2009, 136, 1402–1409. [CrossRef] [PubMed]
73. Hernandez-Vargas, E.A.; Wilk, E.; Canini, L.; Toapanta, F.R.; Binder, S.C.; Uvarovskii, A.; Ross, T.M.;
Guzman, C.A.; Perelson, A.S.; Meyer-Hermann, M. Effects of aging on influenza virus infection dynamics.
J. Virol. 2014, 88, 4123–4131. [CrossRef] [PubMed]
74. Burnham, K.P.; Anderson, D.R.; Huyvaert, K.P. AIC model selection and multimodel inference in behavioral
ecology: Some background, observations, and comparisons. Behav. Ecol. Sociobiol. 2011, 65, 23–35. [CrossRef]
75. Fabozzi, F.J.; Focardi, S.M.; Rachev, S.T.; Arshanapalli, B.G. Appendix E: Model selection criterion: AIC and
BIC. In The Basics of Financial Econometrics; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2014; pp. 399–403.
76. Kenneth, P.; Burnham, D.R.A. Information and Likelihood Theory: A Basis for Model Selection and
Inference. In Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach; Burnham, K.P.,
Anderson, D.R., Eds.; Springer: New York, NY, USA, 2002; pp. 49–97.
77. Summers, J.; Jilbert, A.R.; Yang, W.; Aldrich, C.E.; Saputelli, J.; Litwin, S.; Toll, E.; Mason, W.S. Hepatocyte
turnover during resolution of a transient hepadnaviral infection. Proc. Natl. Acad. Sci. USA 2003, 100,
11652–11659. [CrossRef] [PubMed]
Viruses 2017, 9, 350 17 of 17
78. Malhi, H.; Guicciardi, M.E.; Gores, G.J. Hepatocyte death: A clear and present danger. Physiol. Rev. 2010, 90,
1165–1194. [CrossRef] [PubMed]
79. Guglielmi, A.; Ruzzenente, A.; Conci, S.; Valdegamberi, A.; Iacono, C. How much remnant is enough in liver
resection? Dig. Surg. 2012, 29, 6–17. [CrossRef] [PubMed]
80. Gruttadauria, S.; Parikh, V.; Pagano, D.; Tuzzolino, F.; Cintorino, D.; Miraglia, R.; Spada, M.; Vizzini, G.;
Luca, A.; Gridelli, B. Early regeneration of the remnant liver volume after right hepatectomy for living
donation: a multiple regression analysis. Liver Transplant. 2012, 18, 907–913. [CrossRef] [PubMed]
81. Kishi, Y.; Abdalla, E.K.; Chun, Y.S.; Zorzi, D.; Madoff, D.C.; Wallace, M.J.; Curley, S.A.; Vauthey, J.N.
Three hundred and one consecutive extended right hepatectomies: Evaluation of outcome based on
systematic liver volumetry. Ann. Surg. 2009, 250, 540–548. [CrossRef] [PubMed]
82. Neuschwander-Tetri, B.A.; Unalp, A.; Creer, M.H. Nonalcoholic Steatohepatitis Clinical Research Network.
Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels.
Arch. Intern. Med. 2008, 168, 663–666. [CrossRef] [PubMed]
83. Kim, W.R.; Flamm, S.L.; Di Bisceglie, A.M.; Bodenheimer, H.C. Public Policy Committee of the American
Association for the Study of Liver, D. Serum activity of alanine aminotransferase (ALT) as an indicator of
health and disease. Hepatology 2008, 47, 1363–1370. [CrossRef] [PubMed]
84. Bertoletti, A.; Gehring, A.J. Immune therapeutic strategies in chronic hepatitis B virus infection: Virus or
inflammation control? PLoS Pathog. 2013, 9, e1003784. [CrossRef] [PubMed]
85. Ferrari, C.; Penna, A.; Bertoletti, A.; Valli, A.; Antoni, A.D.; Giuberti, T.; Cavalli, A.; Petit, M.A.; Fiaccadori, F.
Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection.
J. Immunol. 1990, 145, 3442–3449. [PubMed]
86. Bertoletti, A.; Ferrari, C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003,
38, 4–13. [CrossRef] [PubMed]
87. Li, X.; Zhao, J.; Yuan, Q.; Xia, N. Detection of HBV covalently closed circular DNA. Viruses 2017, 9, 139.
[CrossRef] [PubMed]
88. Allweiss, L.; Dandri, M. The role of cccDNA in HBV maintenance. Viruses 2017, 9, 156. [CrossRef] [PubMed]
89. Mason, W.S.; Liu, C.; Aldrich, C.E.; Litwin, S.; Yeh, M.M. Clonal expansion of normal-appearing human
hepatocytes during chronic hepatitis B virus infection. J. Virol. 2010, 84, 8308–8315. [CrossRef] [PubMed]
90. Yeh, C.T.; Chiu, H.T.; Chu, C.M.; Liaw, Y.F. G1 phase dependent nuclear localization of relaxed-circular
hepatitis B virus DNA and aphidicolin-induced accumulation of covalently closed circular DNA. J. Med. Virol.
1998, 55, 42–50. [CrossRef]
91. Ozer, A.; Khaoustov, V.I.; Mearns, M.; Lewis, D.E.; Genta, R.M.; Darlington, G.J.; Yoffe, B. Effect of
hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. Gastroenterology
1996, 110, 1519–1528. [CrossRef] [PubMed]
92. Dandri, M.; Petersen, J. Mechanism of hepatitis B virus persistence in hepatocytes and its carcinogenic
potential. Clin. Infect. Dis. 2016, 62, S281–S288. [CrossRef] [PubMed]
93. Tsiang, M.; Rooney, J.F.; Toole, J.J.; Gibbs, C.S. Biphasic clearance kinetics of hepatitis B virus from patients
during adefovir dipivoxil therapy. Hepatology 1999, 29, 1863–1869. [CrossRef] [PubMed]
94. Nowak, M.A.; Bonhoeffer, S.; Hill, A.M.; Boehme, R.; Thomas, H.C.; McDade, H. Viral dynamics in hepatitis
B virus infection. Proc. Natl. Acad. Sci. USA 1996, 93, 4398–4402. [CrossRef] [PubMed]
95. Ye, B.; Liu, X.; Li, X.; Kong, H.; Tian, L.; Chen, Y. T-cell exhaustion in chronic hepatitis B infection: Current
knowledge and clinical significance. Cell Death Dis. 2015, 6, e1694. [CrossRef] [PubMed]
96. Yi, J.S.; Cox, M.A.; Zajac, A.J. T-cell exhaustion: Characteristics, causes and conversion. Immunology 2010,
129, 474–481. [CrossRef] [PubMed]
97. Miyaoka, Y.; Miyajima, A. To divide or not to divide: Revisiting liver regeneration. Cell Div. 2013, 8, 8.
[CrossRef] [PubMed]
98. Nagasue, N.; Yukaya, H.; Ogawa, Y.; Kohno, H.; Nakamura, T. Human liver regeneration after major hepatic
resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann. Surg. 1987, 206, 30–39.
[CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
